Q-omics provides the consensus-scored SMARCA1 profile across patient tissues and cancer cell-line models. SMARCA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, SMARCA1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SMARCA1 protein abundance shows 25,060 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, THCA, and GBM as cancer lineages where SMARCA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMARCA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMARCA1 survival associations across molecular data types. SMARCA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMARCA1 RNA expression–survival associations across cancer types. High SMARCA1 expression shows unfavorable associations in STAD, BLCA and LGG, but favorable associations in KIRC, THCA and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for SMARCA1 RNA expression.
This table summarizes SMARCA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SMARCA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMARCA1 shows lower tumor expression in THCA, KICH, BLCA, KIRC and BRCA and higher tumor expression in LUAD. The THCA box plot shows higher SMARCA1 RNA expression in normal versus tumor tissue (log2 FC = −1.384, t-test p < 0.001).
This table shows molecular features associated with SMARCA1 in patient tissues and cancer cell lines. In patient samples, SMARCA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMARCA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
